Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

vorable foreign exchange.

LIALDA/MEZAVANT - Ulcerative colitis

LIALDA/MEZAVANT product sales continued to grow in Q3 2011, driven primarily by increased US prescription demand due to higher US market share and the effect of price increases taken since Q3 2010, partially offset by customer destocking in Q3 2011.

VPRIV - Gaucher disease

VPRIV product sales growth was driven by the treatment of new patients, being both naïve patients and switches from CEREZYME. Reported VPRIV sales also benefited from favorable foreign exchange.

INTUNIV - ADHD

INTUNIV product sales were up 50% compared to Q3 2010 primarily driven by strong growth in prescription demand compared to Q3 2010. The growth in product sales was marginally less than the increase in US prescription demand due to de-stocking in Q3 2011 compared to stocking in Q3 2010 and slightly higher sales deductions as a percentage of product sales in Q3 2011.

PENTASA - Ulcerative colitis

The decrease in PENTASA product sales was driven by a decrease in US prescription demand as well as higher destocking in Q3 2011 as compared to Q3 2010. This decrease was partially offset by price increases and lower sales deductions as compared to Q3 2010.

DERMAGRAFT - Diabetic Foot Ulcers ("DFU")

DERMAGRAFT(1) continues to see strong revenue growth in the US, up 27% compared to Q3 2010. The growth resulted from a combination of an expanding US diabetic population, continued adoption of DERMAGRAFT as an efficacious, cost-effective treatment for DFU, and the continued addition of sales representatives to market the product.

(1) Shire acquired DERMAGRAFT through its acquisition of ABH in Q2 2011.

FOSRENOL - Hyperphosphatemia

Product sales of FOSRENOL decreased due to the combined effect of lower US prescription demand resulting from a fall in market share and higher sales deductions in Q3 2011
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 WORMS, GERMANY – ... Co. (NYSE: GRA) announces that its manufacturing facility ... (GMP) certification from EXCiPACT™, an independent organization that ... , All three Grace facilities that ... excipient silica gels have now received GMP certification, ...
(Date:5/26/2015)... RICHMOND, Calif. , May 26, 2015  Sangamo BioSciences, ... Lanphier , Sangamo,s president and CEO, will provide an update ... programs and an overview of the company,s business strategy at ... 2015 Global Healthcare Conference. The conference is being held in ... presentation will be webcast live and may be accessed via ...
(Date:5/26/2015)... Miami, FL (PRWEB) May 26, 2015 ... training, Inc. have announced plans for the company’s first ... 9, 2015, followed by a full day, hands-on stem ... hosted by J. Victor Garcia Gimenez, M.D., President of ... to the medical community’s increasing interest in regenerative medicine ...
(Date:5/26/2015)... May 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced ... convened at Shutters on the Beach in ... status of the Company,s innovative Metronomic Biofeedback Pump (MBP), ... deliver chemotherapy over time to a target site of ... and biofeedback system in real-time.  ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5
... Dec. 21, 2010 Exagen Diagnostics, Inc., a specialty ... today announced that it has been awarded $400,000 in ... program, which was created by Congress as part of ...  Proceeds from the grants will be used to advance ...
... M. Golubieski, president of Foundation Venture Capital Group, LLC, ... Snowdon Inc., a company in which FVCG has invested, ... of Defense (DoD) Program, Transformational Medical Technologies (TMT). ... (DTRA) contract, Snowdon may receive up to $8.2 million ...
... knows how to make an exact cut on a metal rod. ... a carbon nanotube, with a diameter 1/50,000th the thickness of a ... British journal Proceedings of the Royal Society A , researchers ... how single-walled carbon nanotubes are cut, a finding that could lead ...
Cached Biology Technology:Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program 2Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract 2Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract 3How do you cut a nanotube? Lots of compression 2
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... April 21, 2015 High ... policies are boosting access control systems market in ... to a recently published report by TechSci Research " ... the access control systems market in Saudi ... by 2020.The access control systems market in the Kingdom ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... to remove contaminants from soil, scientists at the ... and their Belgium colleagues at Hasselt University have ... on marginal land. The findings, published in the ... Environmental Microbiology , may help scientists design strategies ...
... the FDA has approved the first human clinical trial ... considerations, but not only, or even primarily, because what ... Although deep-seated disagreements about the ethics of embryo ... to focus as well on this being the first ...
... (ACMG) will hold its 16th Annual Clinical Genetics Meeting ... at the Tampa Convention Center. Clinical and medical ... a dizzying pace and the 2009 ACMG Annual Clinical ... and scientific media to learn firsthand about the latest ...
Cached Biology News:Scientists identify bacteria that increase plant growth 2Scientists identify bacteria that increase plant growth 3Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29 2
...
... This monoclonal antibody recognizes 30% of ... individuals. It does not cross-react ... lacking rheumatoid factor nor with pooled ... used in ELISA to detect rheumatoid ...
...
Human VEGF R2 (KDR) MAb (Clone 89106)...
Biology Products: